Hexagon shaped overlay

CAS Life Sciences Data

When making new life sciences discoveries, complete, connected data is crucial for success. Dive deep into relationships between diseases, targets, and novel molecules with the world’s most trusted and reliable source of scientific information, the CAS Content Collection™.

Contact us
Close-up of transparent spherical capsules illuminated in blue, each containing intricate, embedded structures resembling cells or circuits.

Data to accelerate your drug discovery process

Thanks to our hundreds of scientists and deep coverage of scientific literature over the last century, CAS helps drug discovery scientists keep up with the latest breakthroughs and the foundations upon which they are built. Whether you’re looking for disease targets, planning structure-activity-relationship (SAR) studies, assessing the potential for off-target activity, or answering the many pre-investigational new drug (IND) filing questions, save time by leveraging the wealth of existing published data.

SAR, ADME data, toxicity values, and other bioactivity observations and pharmacological data facilitate the discovery of novel targets for therapeutic intervention.

Indexed nucleic acid and protein sequences provide a better understanding of how sequence changes affect biological functions.

Molecular biomarkers used in predictions, diagnoses, and prognoses reveal underlying causes and effects of a disease.

Metabolic signaling pathways and interactions further enable inferences and discoveries of connections between diseases, molecules, and pharmacological responses.

Antibodies, antibody-drug conjugates, antibody-fusion proteins, chimeric antigen receptors, and related engineered proteins hold diagnostic, therapeutic, or immune indications/applications.

Connections between disparate data types reveal reliable critical relationships.

"The comprehensiveness of the CAS database is unparalleled."
TVID: 17E-012-6D1
R&D vice president/director,
Small business pharmaceuticals company
CAS data experts Nicole Stobart, Jeff Wilson, Ph.D., and Mark Schmidt examine the difficulties and importance of creating new authority constructs to organize life sciences data.
Read this executive summary to see how biomarkers could revolutionize cancer care.
Learn more about how the pharma industry is tackling the challenges of drug discovery such as rising costs, and poorly understood disease mechanisms.